Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.

@article{Smith1997EconomicAO,
  title={Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.},
  author={Thomas James Smith and Bruce E. Hillner and Norbert Schmitz and David Christopher Linch and Peter Dreger and Anthony H. Goldstone and Marc A. Boogaerts and Augustin Ferrant and Hartmut Link and Axel Zander and Saul Yanovich and Rob Kitchin and Moshe Haim Erder},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 1},
  pages={5-10}
}
PURPOSE High-dose chemotherapy (HDC) with peripheral-blood progenitor cell (PBPC) and autologous bone marrow (ABM) transplant (T) has documented survival benefits for relapsed Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Treatment costs associated with HDC and its supportive care have restricted its use both on and off clinical trial. In a prospective randomized clinical trial, filgrastim-mobilized PBPCT resulted in faster recovery of bone marrow function, with less hospitalization… CONTINUE READING